The XVII meeting of the Spanish Drug Discovery Network (SDDN) will be held at the will take place at the Hotel Attica in A Coruña on November 20-21, 2025. A benchmark event that has established itself as an ideal space for networking among drug discovery professionals, both from academia and industry.
Each year, we select a set of key topics to foster the exchange of ideas and promote discussions among experts with diverse backgrounds and backgrounds, but with a common goal: to drive the development of new therapies through drug discovery research in a multidisciplinary and translational manner.
As part of its program AseBio organized the round table entitled “Drug Discovery Stories. The path of drug discovery: Lessons from academia and industry”.
Preclinical development of new therapeutics is a complex and multifaceted process. Taking a drug candidate from the laboratory to clinical trials-and ultimately to patients-requires a combination of scientific and non-scientific factors. On the scientific side, it involves identifying a suitable therapeutic target, developing a compound with high efficacy, low toxicity and good bioavailability in the target tissue. But there are also other critical, but sometimes overlooked, factors, such as securing financial resources, gaining access to relevant disease models for proof-of-concept studies, and leveraging previous experience in preclinical development.
In this session we will hear from four promising biotech companies who will share the stories behind their latest drug development programs. They will also reflect on lessons learned along the way. A key point of discussion will be: what role does being (or not being) an academic spin-off play? Has that connection accelerated their development or introduced constraints?
- Ainara Vallejo Fillarramendi (Miramoon) .
- Miriam Corredor (NoctuRNA Therapeutics) “Circular RNA-based therapeutics to treat incurable diseases”.
- Javier Terriente (GT Drug Discovery, ZeCardio) “Using zebrafish to discover cardiac regeneration in humans”.
- Sonia Martínez Arca (Batea Oncology) “Transformation of glioblastoma into a disease that responds to treatment”.